With a $25 million grant from PCORI, the Penn team will launch a randomized controlled trial to see if their game reduces the ...
Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and ...
Turkey: A pilot study published in BMC Ophthalmology suggests that a gamified, app-based multimodal visual therapy may offer ...
Bristol-Myers Squibb Company ($BMY) announced an update on their ongoing clinical study. Study Overview Bristol-Myers Squibb ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Dr. Raza Bokhari, Executive Chairman & CEO of Medicus will deliver a company presentation as Medicus enters 2026 with multiple Phase 2 Catalysts across clinical, regulatory, and pipeline expansion ...
Patients with ABI require prolonged mechanical ventilation and have a substantially higher risk for VAP due to impaired airway protection and injury-related immune dysfunction. However, routine use of ...
SynuSight Biotech has licensed 18F-FD4 to XingImaging and to ABLi Therapeutics to evaluate alpha-synuclein clearance from the brain in response to risvodetinib treatment ...
In summary, we are making significant strides in advancing BOT/BAL and positioning Agenus for long-term success. I'll now ...
MapLight Therapeutics, Inc. ('MapLight”) (Nasdaq: MPLT) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ML-007C-MA, an investigational novel ...
Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback